CD16 is a cluster of differentiation molecule expressed on the surface of natural killer (NK) cells, monocytes, macrophages and neutrophil polymorphonuclear leukocytes. It is identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b) and involved in antibody-dependent cellular cytotoxicity (ADCC). Binding of CD16 to the Fc domain of IgG antibodies result in cross-linking of CD16 on the surface of effector cells such as NK cells. This cross-linking induces increased intracellular Ca2+ levels and a cascade of signal transduction and eventually activates the effector cells.
Antibody-dependent cellular cytotoxicity in therapeutic antibody treatment
Front Immunol. 2013; 4: 76.
CD16 CAR-T Cell Therapy
In a preclinical study, a CAR construct consisting of a high-affinity CD16 variant, hinge and transmembrane domains, and signal domains from CD3ζ and 4-1BB (TNFRSF9) is transduced into T cells. These CAR-T cells, which are administrated in combination with therapeutic monoclonal antibodies (mAbs), specifically kill the tumor cells at a low effector-target ratio. Similar results are obtained with many other mAbs such as anti-CD20 antibody (rituximab), anti-HER2 antibody (trastuzumab) and anti-GD2 antibody. Therefore, the CD16 CAR has the potential to be a universal chimeric receptor to enhance the efficacy of therapeutic antibodies for cancer treatment. In order to validate this discovery, patients with B cell malignancies are given autologous CD16 CAR-T cells in combination with anti-CD20 mAb rituximab to assess the feasibility, safety and efficacy of the therapy.
The animal models used for CD16 CAR-T cell therapy research are developed by the target of co-administered monoclonal antibody. Different kinds of cancer models have been established for the in vivo assay of CD16 CAR-T cells in our facility. Our scientists use multiple kinds of cancer cell lines or human primary cancer cells to develop xenograft cancer models in immunodeficiency mice. We also provide rats and non-humfan primates (NHPs) models to meet your special requirement.
In vivo Assay Parameters and Techniques
At Creative Biolabs, we offer the most exquisite and comprehensive service platform forCD16 CAR-T cell therapy research.
Tumor remission monitored by tumor cell analysis or bioluminescence imaging and survival curve tracking.
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
GLP-Compliant Preclinical Test
All our experiments are performed by well-trained and experienced technicians in a GLP-compliant and IACUC-regulated facility.
Creative Biolabs is ready to provide assistance for your CD16 CAR-T preclinical in vivo assay. Our exceptional team of scientists design and perform CAR-Tassays ranging from development of animal models to the evaluation of efficacy, safety, viability and bio-distribution of CD16 CAR-T cells. We also offer a broad range of animal models including rats and non-human primates (NHPs).
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE